{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T15:53:36Z","timestamp":1778946816853,"version":"3.51.4"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2020,4,19]],"date-time":"2020-04-19T00:00:00Z","timestamp":1587254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Merck Sharp & Dohme Corp"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>In Europe, increases in HCV infection have been observed over the last two decades in MSM, making them a key population for recently acquired HCV. Alternative combinations of direct-acting antiviral agents against early HCV infection need to be assessed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients and methods<\/jats:title>\n                  <jats:p>In this pilot trial, MSM with recently acquired genotype 1 or 4 HCV infection were prospectively included and received 8\u2009weeks of oral grazoprevir 100\u2009mg and elbasvir 50\u2009mg in a fixed-dose combination administered once daily. The primary endpoint was sustained virological response evaluated 12\u2009weeks after the end of treatment (EOT) (SVR12). Secondary endpoints were the virological characterization of failures, the quality of life before, during and after treatment and the rate of reinfection.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In a 15\u2009month period, 30 patients were enrolled, all of whom were MSM. Of the 29 patients completing follow-up, 28 (96%, 95% CI\u2009=\u200982%\u201399%) achieved SVR12. One patient interrupted follow-up (suicide) but had undetectable plasma HCV RNA at EOT. One patient with suboptimal adherence confirmed by plasma drug monitoring relapsed and developed NS3, NS5A and NS5B resistance-associated substitutions (V36M, M28V and S556G). The most common adverse events related to study drug were diarrhoea (n\u2009=\u20094, 13%), insomnia (n\u2009=\u20092, 7%) and fatigue (n\u2009=\u20092, 7%), although no patient discontinued treatment. No HIV RNA breakthrough was reported in the 28 patients with HIV coinfection. At Week 48, reinfection was diagnosed in three patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Our data support the use of grazoprevir\/elbasvir for immediate treatment against HCV in order to reduce HCV transmission in MSM.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkaa091","type":"journal-article","created":{"date-parts":[[2020,3,3]],"date-time":"2020-03-03T20:18:24Z","timestamp":1583266704000},"page":"1961-1968","source":"Crossref","is-referenced-by-count":9,"title":["Grazoprevir\/elbasvir for the immediate treatment of recently acquired HCV genotype 1 or 4 infection in MSM"],"prefix":"10.1093","volume":"75","author":[{"given":"Anders","family":"Boyd","sequence":"first","affiliation":[{"name":"INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, F-75012 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Miailhes","sequence":"first","affiliation":[{"name":"H\u00f4pital de la Croix-Rousse, Hospices Civils de Lyon, Service de Maladies Infectieuses et Tropicales, Lyon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Chas","sequence":"first","affiliation":[{"name":"AP-HP, H\u00f4pital Tenon, Service de Maladies Infectieuses et tropicales, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc-Antoine","family":"Valantin","sequence":"first","affiliation":[{"name":"AP-HP, Groupe Hospitalier Piti\u00e9-Salp\u00eatri\u00e8re, Service de Maladies Infectieuses et tropicales, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yazdan","family":"Yazdanpanah","sequence":"first","affiliation":[{"name":"AP-HP, H\u00f4pital Bichat-Claude Bernard, Service de Maladies Infectieuses et tropicales, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Rosenthal","sequence":"first","affiliation":[{"name":"H\u00f4pital de l\u2019Archet, Service de m\u00e9decine interne, Nice, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephane","family":"Chevaliez","sequence":"first","affiliation":[{"name":"AP-HP, d\u00e9partement de Virologie, H\u00f4pital Henri Mondor, National Reference Center for Viral Hepatitis B, C and delta, INSERM U955, Cr\u00e9teil, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lionel","family":"Piroth","sequence":"first","affiliation":[{"name":"D\u00e9partement d\u2019infectiologie, CHU de Dijon, 21079 Dijon, France; INSERM CIC 1432, Universit\u00e9 de Bourgogne, 21079 Dijon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hayette","family":"Rougier","sequence":"first","affiliation":[{"name":"Institut de M\u00e9decine et d\u2019Epid\u00e9miologie Appliqu\u00e9e, Paris"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilles","family":"Peytavin","sequence":"first","affiliation":[{"name":"AP-HP, H\u00f4pital Bichat-Claude Bernard, Laboratoire de Pharmacologie-Toxicologie and IAME, UMR 1137, Universit\u00e9 Paris Diderot, Sorbonne Paris Cit\u00e9 and INSERM, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilles","family":"Pialoux","sequence":"first","affiliation":[{"name":"AP-HP, H\u00f4pital Tenon, Service de Maladies Infectieuses et tropicales, Paris, France"},{"name":"Sorbonne Universit\u00e9, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre-Marie","family":"Girard","sequence":"first","affiliation":[{"name":"Service de maladies infectieuses et tropicales, H\u00f4pital St Antoine, AP-HP, Paris, France"},{"name":"Sorbonne Universit\u00e9, INSERM UMR-S1136, Institut Pierre Louis de Sant\u00e9 Publique, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karine","family":"Lacombe","sequence":"first","affiliation":[{"name":"Service de maladies infectieuses et tropicales, H\u00f4pital St Antoine, AP-HP, Paris, France"},{"name":"Sorbonne Universit\u00e9, INSERM UMR-S1136, Institut Pierre Louis de Sant\u00e9 Publique, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,4,19]]},"reference":[{"key":"2020061904541764800_dkaa091-B1","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","article-title":"EASL recommendations on treatment of hepatitis C 2018","volume":"69","year":"2018","journal-title":"J Hepatol"},{"key":"2020061904541764800_dkaa091-B2","year":"2017"},{"key":"2020061904541764800_dkaa091-B3","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1053\/j.gastro.2009.02.006","article-title":"Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men","volume":"136","author":"van de Laar","year":"2009","journal-title":"Gastroenterology"},{"key":"2020061904541764800_dkaa091-B4","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jhep.2017.03.038","article-title":"Lack of decline in hepatitis C virus incidence among HIV-positive men who have sex with men during 1990\u20132014","volume":"67","author":"van Santen","year":"2017","journal-title":"J Hepatol"},{"key":"2020061904541764800_dkaa091-B5","article-title":"High incidence of HCV in HIV-negative men who have sex with men using pre-exposure prophylaxis","author":"Hoornenborg","year":"2019","journal-title":"J Hepatol"},{"key":"2020061904541764800_dkaa091-B6","first-page":"561","article-title":"High number of potential transmitters revealed in a population-based systematic hepatitis C virus RNA screening among human immunodeficiency virus-infected men who have sex with men","volume":"68","author":"Braun","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2020061904541764800_dkaa091-B7","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/hep.29611","article-title":"Should we treat acute hepatitis C? A decision and cost-effectiveness analysis","volume":"67","author":"Bethea","year":"2018","journal-title":"Hepatology"},{"key":"2020061904541764800_dkaa091-B8","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1093\/ije\/dyx075","article-title":"Behavioural, not biological, factors drive the HCV epidemic among HIV-positive MSM: HCV and HIV modelling analysis including HCV treatment-as-prevention impact","volume":"46","author":"MacGregor","year":"2017","journal-title":"Int J Epidemiol"},{"key":"2020061904541764800_dkaa091-B9","doi-asserted-by":"crossref","first-page":"e0210179","DOI":"10.1371\/journal.pone.0210179","article-title":"Early treatment of acute hepatitis C infection is cost-effective in HIV-infected men-who-have-sex-with-men","volume":"14","author":"Popping","year":"2019","journal-title":"PLoS One"},{"key":"2020061904541764800_dkaa091-B10","doi-asserted-by":"crossref","first-page":"ofy238","DOI":"10.1093\/ofid\/ofy238","article-title":"Ledipasvir and sofosbuvir in the treatment of early hepatitis C virus infection in HIV-infected men","volume":"5","author":"Palaniswami","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"2020061904541764800_dkaa091-B11","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S2468-1253(17)30003-1","article-title":"Ledipasvir-sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection: an open-label, single-arm trial","volume":"2","author":"Rockstroh","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2020061904541764800_dkaa091-B12","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1093\/cid\/cix025","article-title":"Sofosbuvir plus ribavirin without interferon for treatment of acute hepatitis C virus infection in HIV-1-infected individuals: SWIFT-C","volume":"64","author":"Naggie","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2020061904541764800_dkaa091-B13","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/jvh.12917","article-title":"Shortened therapy of eight weeks with paritaprevir\/ritonavir\/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection","volume":"25","author":"Martinello","year":"2018","journal-title":"J Viral Hepat"},{"key":"2020061904541764800_dkaa091-B14","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(14)61795-5","article-title":"Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial","volume":"385","author":"Lawitz","year":"2015","journal-title":"Lancet"},{"key":"2020061904541764800_dkaa091-B15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/M15-0785","article-title":"Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial","volume":"163","author":"Zeuzem","year":"2015","journal-title":"Ann Intern Med"},{"key":"2020061904541764800_dkaa091-B16","doi-asserted-by":"crossref","first-page":"e319","DOI":"10.1016\/S2352-3018(15)00114-9","article-title":"Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial","volume":"2","author":"Rockstroh","year":"2015","journal-title":"Lancet HIV"},{"key":"2020061904541764800_dkaa091-B17","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S0140-6736(14)61793-1","article-title":"Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV\/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial","volume":"385","author":"Sulkowski","year":"2015","journal-title":"Lancet"},{"key":"2020061904541764800_dkaa091-B18","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1093\/cid\/ciy547","article-title":"High cure rates with grazoprevir-elbasvir with or without ribavirin guided by genotypic resistance testing among human immunodeficiency virus\/hepatitis C virus-coinfected men who have sex with men","volume":"68","author":"Braun","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2020061904541764800_dkaa091-B19","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S2468-1253(18)30414-X","article-title":"Treatment of acute hepatitis C genotypes 1 and 4 with 8 weeks of grazoprevir plus elbasvir (DAHHS2): an open-label, multicentre, single-arm, phase 3b trial","volume":"4","author":"Boerekamps","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2020061904541764800_dkaa091-B20","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/bmc.865","article-title":"Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry","volume":"21","author":"Jung","year":"2007","journal-title":"Biomed Chromatogr"},{"key":"2020061904541764800_dkaa091-B21","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jchromb.2019.01.024","article-title":"Quantification of second generation direct-acting antivirals daclatasvir, elbasvir, grazoprevir, ledipasvir, simeprevir, sofosbuvir and velpatasvir in human plasma by UPLC-MS\/MS","volume":"1110\u20131","author":"van Seyen","year":"2019","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"2020061904541764800_dkaa091-B22"},{"key":"2020061904541764800_dkaa091-B23","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1002\/hep.28491","article-title":"Retreatment with sofosbuvir and simeprevir of patients with hepatitis C virus genotype 1 or 4 who previously failed a daclatasvir-containing regimen","volume":"63","author":"Hezode","year":"2016","journal-title":"Hepatology"},{"key":"2020061904541764800_dkaa091-B24","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3851\/IMP3318","article-title":"Performance assessment of a fully automated deep sequencing platform for HCV resistance testing","volume":"24","author":"Rodriguez","year":"2019","journal-title":"Antivir Ther"},{"key":"2020061904541764800_dkaa091-B25","doi-asserted-by":"crossref","first-page":"S110","DOI":"10.1016\/S0168-8278(18)30437-9","article-title":"High efficacy and safety of grazoprevir and elbasvir for 8 weeks in treatment-naive, non-severe fibrosis HCV GT1b-infected patients: interim results of the STREAGER study","volume":"68 Suppl 1","author":"Abergel","year":"2018","journal-title":"J Hepatol"},{"key":"2020061904541764800_dkaa091-B26","first-page":"646","article-title":"Efficacy and safety of elbasvir\/grazoprevir for 8 or 12 weeks in participants with hepatitis C virus genotype 4 infection","volume":"68","author":"Asselah","year":"2018","journal-title":"Hepatology"},{"key":"2020061904541764800_dkaa091-B27","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/infdis\/jiz154","article-title":"An open-label, randomized, active-controlled trial of 8 versus 12 weeks of elbasvir\/grazoprevir for treatment-naive patients with chronic hepatitis C genotype 1b infection and mild fibrosis (EGALITE Study): impact of baseline viral loads and NS5A resistance-associated substitutions","volume":"220","author":"Huang","year":"2019","journal-title":"J Infect Dis"},{"key":"2020061904541764800_dkaa091-B28","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1097\/QAD.0000000000002138","article-title":"Progression of liver fibrosis following acute hepatitis C virus infection in HIV-positive MSM","volume":"33","author":"Newsum","year":"2019","journal-title":"AIDS"},{"key":"2020061904541764800_dkaa091-B29","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/jvh.13037","article-title":"The accuracy of baseline viral load for predicting the efficacy of elbasvir\/grazoprevir in participants with hepatitis C virus genotype 1a infection: an integrated analysis","volume":"26","author":"Serfaty","year":"2019","journal-title":"J Viral Hepat"},{"key":"2020061904541764800_dkaa091-B30","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/cid\/civ402","article-title":"Hepatitis C virus RNA levels during interferon-free combination direct-acting antiviral treatment in registrational trials","volume":"61","author":"Harrington","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2020061904541764800_dkaa091-B31","doi-asserted-by":"crossref","first-page":"593","DOI":"10.3851\/IMP3253","article-title":"Interim analysis of a 3-year follow-up study of NS5A and NS3 resistance-associated substitutions after treatment with grazoprevir-containing regimens in participants with chronic HCV infection","volume":"23","author":"Lahser","year":"2018","journal-title":"Antivir Ther"},{"key":"2020061904541764800_dkaa091-B32","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1053\/jhep.2002.31311","article-title":"Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients","volume":"35","author":"Bernstein","year":"2002","journal-title":"Hepatology"},{"key":"2020061904541764800_dkaa091-B33","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/apt.13269","article-title":"The patient\u2019s journey with chronic hepatitis C from interferon plus ribavirin to interferon- and ribavirin-free regimens: a study of health-related quality of life","volume":"42","author":"Younossi","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"2020061904541764800_dkaa091-B34","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.2147\/PPA.S172732","article-title":"Patient-reported outcomes in individuals with hepatitis C virus infection treated with elbasvir\/grazoprevir","volume":"12","author":"Ng","year":"2018","journal-title":"Patient Prefer Adherence"},{"key":"2020061904541764800_dkaa091-B35","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/add.14774","article-title":"Identification and characterization of latent classes based on drug use among men who have sex with men at risk of sexually transmitted infections in Amsterdam, the Netherlands","volume":"115","author":"Achterbergh","year":"2020","journal-title":"Addiction"},{"key":"2020061904541764800_dkaa091-B36","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1471-244X-8-70","article-title":"A systematic review of mental disorder, suicide, and deliberate self harm in lesbian, gay and bisexual people","volume":"8","author":"King","year":"2008","journal-title":"BMC Psychiatry"},{"key":"2020061904541764800_dkaa091-B37","doi-asserted-by":"crossref","first-page":"ofw105","DOI":"10.1093\/ofid\/ofw105","article-title":"Antiretroviral use in the CEASE Cohort Study and implications for direct-acting antiviral therapy in human immunodeficiency virus\/hepatitis C virus coinfection","volume":"3","author":"Martinello","year":"2016","journal-title":"Open Forum Infect Dis"},{"key":"2020061904541764800_dkaa091-B38","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1111\/liv.13727","article-title":"Efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 4 infection: a pooled analysis","volume":"38","author":"Asselah","year":"2018","journal-title":"Liver Int"},{"key":"2020061904541764800_dkaa091-B39","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1053\/j.gastro.2016.09.045","article-title":"Effectiveness of elbasvir and grazoprevir combination, with or without ribavirin, for treatment-experienced patients with chronic hepatitis C infection","volume":"152","author":"Kwo","year":"2017","journal-title":"Gastroenterology"},{"key":"2020061904541764800_dkaa091-B40","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00535-018-1429-3","article-title":"The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection","volume":"53","author":"Zeuzem","year":"2018","journal-title":"J Gastroenterol"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/75\/7\/1961\/33404996\/dkaa091.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/75\/7\/1961\/33404996\/dkaa091.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T08:56:02Z","timestamp":1592556962000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/75\/7\/1961\/5822569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,19]]},"references-count":40,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2020,4,19]]},"published-print":{"date-parts":[[2020,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaa091","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,7]]},"published":{"date-parts":[[2020,4,19]]}}}